Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) — Form 144: Proposed sale of shares
Summary from the key facts
GEORGE L. SING filed notice of a proposed sale of 21,129 Common shares of Regeneron Pharmaceuticals, Inc. (about $20.4M) on or around Nov 2, 2026 through Morgan Stanley Smith Barney LLC Executive Financial Services.
Key facts
- Seller
- GEORGE L. SING
- Relationship
- Director
- Shares to sell
- 21,129
- Market value
- $20,376,359.76
- Approximate sale date
- Nov 2, 2026
- Broker
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Acquired (1)
- Nov 2, 2026 · Exercise of Options Under a Registered Plan
- Acquired (2)
- Dec 30, 2025 · Previously Exercised Options
- Acquired (3)
- Nov 2, 2026 · Exercise of Options Under a Registered Plan
- Acquired (4)
- Nov 2, 2026 · Exercise of Options Under a Registered Plan
- Acquired (5)
- Jan 2, 2026 · Previously Exercised Options
- Acquired (6)
- Nov 2, 2026 · Exercise of Options Under a Registered Plan
- Acquired (7)
- May 3, 2024 · Previously Exercised Options
- Acquired (8)
- Nov 2, 2026 · Exercise of Options Under a Registered Plan
- Acquired (9)
- Nov 2, 2026 · Exercise of Options Under a Registered Plan
- Acquired (10)
- Dec 31, 2024 · Previously Exercised Options
More REGN filings
- 144
Filed Nov 2, 2026
- 144
Filed Nov 2, 2026
- 144
Filed Oct 30, 2026
- 144
Filed Oct 30, 2026
- 144
Filed Oct 30, 2026
- 10-Q
Filed Oct 30, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.